- Indications and Usage Hyperammonemia: Indicated for the treatment of hyperammonemia associated with acute and chronic liver diseases (such as liver cirrhosis, fatty liver, and hepatitis). Hepatic Encephalopathy: Particularly suitable for the treatment of early-stage consciousness disorders or neurological complications (hepatic encephalopathy) caused by liver dysfunction.
- Dosage and Administration Adult Dosage: The usual dosage is 5 g per administration, 2 to 3 times daily. Administration Details: The contents of each packet should be dissolved in an appropriate amount of liquid (such as water, tea, or fruit juice) and taken before or after meals. Severe Cases: In cases of severe chronic liver disease or early-stage hepatic coma, the dosage can be increased as clinically necessary.
- Mechanism of Action Urea Cycle Stimulation: L-ornithine acts as a substrate for the synthesis of urea and glutamine, activating the urea cycle and promoting the detoxification of ammonia. Energy Metabolism: L-aspartate participates in the synthesis of nucleic acids in hepatocytes to facilitate the repair of damaged cells and indirectly promotes energy generation in the tricarboxylic acid (TCA) cycle.
- Safety and Warnings Renal Impairment: Contraindicated in patients with severe renal failure (serum creatinine > 3 mg/100 mL). Hypersensitivity: Contraindicated in patients with known allergies to amino acid preparations. Monitoring: When used in large doses, serum and urine urea levels should be monitored.
- Adverse Reactions and Clinical Research Most Common Adverse Reactions: Nausea, vomiting, or abdominal discomfort may occur occasionally. Clinical Research: Clinical evidence supports its efficacy in lowering blood ammonia levels and improving cognitive function in patients with hepatic encephalopathy.
- Drug Interactions General Profile: Specific drug-drug interactions have not been fully characterized. Coadministration: Generally safe to use with other liver-protective agents, antibiotics, or laxatives commonly prescribed for hepatic encephalopathy, but concurrent use should be managed by a physician.
- Pharmaceutical Information Chemical Composition: Active ingredients include L-ornithine and L-aspartate. Appearance: White or off-white granules with a sweet and sour taste. Storage: Keep in a sealed container, protected from light and moisture.
Ruigan L-Ornithine L-Aspartate Granules
Brand Name: 瑞甘 ®（Ruigan®）
Generic Name: L-Ornithine L-Aspartate
Strength: 3g per sachet, 10 sachets per box
Manufacturer: Wuhan Qirui Pharmaceuticals Co., Ltd.
Marketing Authorization Holder: Wuhan Qirui Pharmaceuticals Co., Ltd.
Approval Date in China: March 25, 2009
Registration Number:国药准字H20090160
Storage: Store tightly sealed, protected from light, and preserved at dry place below 30°C. Refer to the full package insert for detailed storage specifications.
Price&Cost:Contact Us now for the best price of L-Ornithine L-Aspartate（Ruigan）
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.